Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab for connective tissue disease-associated interstitial lung disease
2024-513018-36-00Phase 3Authorised
- Sponsor
- GSK
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in connective tissue disease-associated interstitial lung disease (CTD-ILD) comparing Benlysta with Placebo (2 arms). Primary endpoint: Absolute change from baseline in forced vital capacity. Planned start Mar 2025; status: authorised.
02
Drugs
belimumab
03
Conditions
connective tissue disease-associated interstitial lung disease (CTD-ILD)
Beyond the preview
Go deeper on 2024-513018-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513018-36-00.